rasagiline prodrug (HNC364) / Henovcom - LARVOL DELTA

Relative Bioavailability Study of HNC364 Injectable Suspension (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease • CYP1A2

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Trial completion date: Dec 2023 ➔ May 2024 | Trial primary completion date: Sep 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease • CYP1A2

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | N=18 ➔ 34

Enrollment change • CNS Disorders • Movement Disorders • Parkinson's Disease • CYP1A2

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Trial completion date: Apr 2023 ➔ Dec 2023 | Trial primary completion date: Feb 2023 ➔ Sep 2023

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease • CYP1A2

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease • CYP1A2